Trial Profile
A Single-arm, Single Center, Pilot Study of Siltuximab, an Anti-IL6 Therapy, for Patients With Myelofibrosis
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase 0
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Siltuximab (Primary)
- Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
- Focus Adverse reactions
- 21 Oct 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 23 Jun 2016 New trial record